Emerging viral diseases from a vaccinology perspective

Nature Immunology

19, 20-28

DOI: 10.1038/s41590-017-0007-9

Citation Report

#	Article	IF	Citations
1	China-invented vaccines against vaccine-preventable diseases for Belt & Road countries. Global Health Journal (Amsterdam, Netherlands), 2017, 1, 11-19.	1.9	1
2	Novel Vaccine Technologies. JAMA - Journal of the American Medical Association, 2018, 319, 1431.	3.8	73
3	New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue. Frontiers in Immunology, 2018, 9, 1432.	2.2	115
4	Editorial: Zika Virus Research. Frontiers in Neurology, 2018, 9, 168.	1.1	2
5	Cryfa: a secure encryption tool for genomic data. Bioinformatics, 2019, 35, 146-148.	1.8	19
7	Preparing for the Next Influenza Pandemic: The Development of a Universal Influenza Vaccine. Journal of Infectious Diseases, 2019, 219, S107-S109.	1.9	12
8	New and emerging infectious diseases (Ebola, Middle Eastern respiratory syndrome coronavirus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 germicide susceptibility. American Journal of Infection Control, 2019, 47, A29-A38.	1.1	24
9	Structural Vaccinology for Viral Vaccine Design. Frontiers in Microbiology, 2019, 10, 738.	1.5	47
10	Commentary on â€œCurrent Challenges in the Development of Vaccines and Drugs Against Emerging Vector-borne Diseasesâ€•by Professor Kwang-sun Kim, Pusan National University, Republic of Korea. Current Medicinal Chemistry, 2019, 26, 3201-3204.	1.2	1
11	Insights into innate and adaptive immune responses in vaccine development against EV-A71. , 2019, 7, 251513551988899.	1.4	15
12	Influenza Vaccination to Reduce Cardiovascular Morbidity and Mortality in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 1777-1794.	1.2	57
13	PriorizaciÃ³n de nuevas vacunas e innovaciÃ³n al servicio de estrategias de vacunaciÃ³n. Revista MÃ©dica ClÃnica Las Condes, 2020, 31, 343-351.	0.2	0
14	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 2020, 586, 567-571.	13.7	1,153
15	Conspiracy Beliefs Are Associated with Lower Knowledge and Higher Anxiety Levels Regarding COVID-19 among Students at the University of Jordan. International Journal of Environmental Research and Public Health, 2020, 17, 4915.	1.2	155
16	The Latest Achievements in the Construction of Influenza Virus Detection Aptasensors. Viruses, 2020, 12, 1365.	1.5	5
17	Antiphage activity of natural and synthetic substances: a new age for antivirals?. Future Microbiology, 2020, 15, 767-777.	1.0	3
18	Engineering nanoparticulate vaccines for enhancing antigen cross-presentation. Current Opinion in Biotechnology, 2020, 66, 113-122.	3.3	43
19	Vaccines targeting SARS-CoV-2 tested in humans. Nature Medicine, 2020, 26, 1336-1338.	15.2	7

#	Article	IF	Citations
20	Study on Adenovirus Infection in vitro with Nanoself-Assembling Peptide as Scaffolds for 3D Culture . International Journal of Nanomedicine, 2020, Volume 15, 6327-6338.	3.3	5
21	A Narrative Review of Emerging Therapeutics for COVID-19. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2020, 4, 745-758.	1.2	7
22	Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist. Antibiotics, 2020, 9, 255.	1.5	4
23	Induction of mucosal immunity against pathogens by using recombinant baculoviral vectors: Mechanisms, advantages, and limitations. Journal of Leukocyte Biology, 2020, 108, 835-850.	1.5	5
24	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. Cell, 2020, 181, 1458-1463.	13.5	92
25	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Frontiers in Immunology, 2020, 11, 842.	2.2	36
26	An update on antiviral antibody-based biopharmaceuticals. International Immunopharmacology, 2020, 86, 106760.	1.7	19
27	Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases. Annals of Internal Medicine, 2021, 174, 326-334.	2.0	11
28	Diverse roles of long nonâ€coding RNAs in viral diseases. Reviews in Medical Virology, 2021, 31, e2198.	3.9	16
29	Genomic Medicine and Advances in Vaccine Technology and Development in the Developing and Developed World. Vaccines, 2021, 9, 9.	2.1	5
30	Promoting versatile vaccine development for emerging pandemics. Npj Vaccines, 2021, 6, 26.	2.9	26
31	A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach. Frontiers in Immunology, 2021, 12, 598778.	2.2	14
32	Biosecurity risks associated with vaccine platform technologies. Vaccine, 2022, 40, 2514-2523.	1.7	9
33	Harnessing biomaterials for therapeutic strategies against COVID-19. Emergent Materials, 2021, 4, 9-18.	3.2	9
34	Profiling of the immune repertoire in COVID-19 patients with mild, severe, convalescent, or retesting-positive status. Journal of Autoimmunity, 2021, 118, 102596.	3.0	27
35	Barriers Influencing Vaccine Development Timelines, Identification, Causal Analysis, and Prioritization of Key Barriers by KOLs in General and Covid-19 Vaccine R&D. Frontiers in Public Health, 2021, 9, 612541.	1.3	8
36	Mitigating Future Respiratory Virus Pandemics: New Threats and Approaches to Consider. Viruses, 2021, 13, 637.	1.5	21
37	3D Cell Culture Models in COVID-19 Times: A Review of 3D Technologies to Understand and Accelerate Therapeutic Drug Discovery. Biomedicines, 2021, 9, 602.	1.4	12

#	Article	IF	Citations
38	Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade. Expert Opinion on Drug Discovery, 2021, 16, 961-975.	2.5	15
39	Emerging Infection, Vaccination, and Guillainâ€“BarrÃ© Syndrome: A Review. Neurology and Therapy, 2021, 10, 523-537.	1.4	40
40	Development of a Modular Vaccine Platform for Multimeric Antigen Display Using an Orthobunyavirus Model. Vaccines, 2021, 9, 651.	2.1	16
41	Maintaining international research collaborations in the setting of a pandemic: Approach in Indonesia. Journal of Global Health, 2021, 11, 03087.	1.2	2
42	Biomaterials and Oxygen Join Forces to Shape the Immune Response and Boost COVIDâ€19 Vaccines. Advanced Science, 2021, 8, 2100316.	5.6	17
43	Modeling Human Viral Diseases: Trials and Triumphs. Frontiers in Virology, 2021, 1, .	0.7	2
44	The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction. Current Pharmaceutical Biotechnology, 2022, 23, 1118-1129.	0.9	9
45	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	6.6	165
46	Advancing sustainable development goals through immunization: a literature review. Globalization and Health, 2021, 17, 95.	2.4	35
47	Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection. Frontiers in Immunology, 2021, 12, 721328.	2.2	28
48	Challenges towards serologic diagnostics of emerging arboviruses. Clinical Microbiology and Infection, 2021, 27, 1221-1229.	2.8	25
49	COVID 19: Causal Loop Diagramming (CLD) of Social-Ecological Interactions for Teaching Sustainable Development. World Sustainability Series, 2021, , 311-330.	0.3	0
50	Comparison of two pandemics: H1N1 and SARS-CoV-2. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2021, 67, 115-119.	0.3	2
51	Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19. Life Sciences, 2020, 255, 117842.	2.0	91
52	While We Endure This Pandemic, What New Respiratory Virus Threats Are We Missing?. Open Forum Infectious Diseases, 2021, 8, ofab078.	0.4	10
55	Prototype pathogen approach for pandemic preparedness: world on fire. Journal of Clinical Investigation, 2020, 130, 3348-3349.	3.9	33
56	Which Plagues are Coming Next?. , 0, , .		0
57	Travel, Migration and Emerging Infectious Diseases. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2018, 29, 175-179.	0.7	14

#	Article	IF	Citations
58	Nanovaccines Mediated Subcutisâ€toâ€Intestine Cascade for Improved Protection against Intestinal Infections. Small, 2022, 18, e2105530.	5.2	4
59	Pharmacological Agents for COVID-19 Patients. , 2021, , 151-166.		0
60	The Role of Bioeconomy in the Future Energy Scenario: A State-of-the-Art Review. Sustainability, 2022, 14, 560.	1.6	16
61	The next major emergent infectious disease: reflections on vaccine emergency development strategies. Expert Review of Vaccines, 2022, 21, 471-481.	2.0	9
62	An Overview of Veterinary Viral Diseases and Vaccine Technologies. Methods in Molecular Biology, 2022, 2465, 1-26.	0.4	3
63	FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D. PLoS ONE, 2022, 17, e0262149.	1.1	6
64	Leishmaniac Quest for Developing a Novel Vaccine Platform. Is a Roadmap for Its Advances Provided by the Mad Dash to Produce Vaccines for COVID-19?. Vaccines, 2022, 10, 248.	2.1	1
65	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	2.2	21
66	Emerging Viral Infections, Hypertension, and Cardiovascular Disease in Sub-Saharan Africa: A Narrative Review. Hypertension, 2022, , HYPERTENSIONAHA12117949.	1.3	1
67	Delivering Pandemic Vaccines in 100 Days â€" What Will It Take?. New England Journal of Medicine, 2022, 387, e3.	13.9	36
69	Carbohydrate-based drugs launched during 2000â^'2021. Acta Pharmaceutica Sinica B, 2022, 12, 3783-3821.	5.7	68
70	Synthetic antiviral peptides: a new way to develop targeted antiviral drugs. Future Virology, 2022, 17, 577-591.	0.9	4
71	Futurology and monitoring in the field of virology to deal with emerging diseases. , 2022, 125, 253-263.		0
72	A generalizable framework for enhanced natural climate solutions. Plant and Soil, 2022, 479, 3-24.	1.8	6
73	Proteases and HPV-Induced Carcinogenesis. Cancers, 2022, 14, 3038.	1.7	7
74	Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic. Biosafety and Health, 2022, 4, 347-363.	1.2	2
75	Vaccines, antivirals, and the beneficial uses of viruses. , 2023, , 145-168.		0
76	Clinical and epidemiological aspects of severe acute respiratory infection: before and during the first year of the COVID-19 pandemic in Brazil. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2023, 117, 161-173.	0.7	2

#	Article	IF	Citations
77	Antiviral potential of nanomaterials: The fight against viruses. , 2023, , 101-132.		0
78	Vaccines against Emerging and Neglected Infectious Diseases: An Overview. Vaccines, 2022, 10, 1385.	2.1	8
79	Primate hemorrhagic fever-causing arteriviruses are poised for spillover to humans. Cell, 2022, 185, 3980-3991.e18.	13.5	16
81	Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity. Journal of Clinical Investigation, 2022, 132, .	3.9	12
82	Therapeutic strategy targeting host lipolysis limits infection by SARS-CoV-2 and influenza A virus. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	14
83	Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice. IScience, 2022, 25, 105324.	1.9	2
84	Spy&IAC enables specific capture of SpyTagged proteins for rapid assembly of plug-and-display nanoparticle vaccines. International Journal of Biological Macromolecules, 2023, 226, 240-253.	3.6	2
85	The need and challenges for development of vaccines against emerging infectious diseases. Jornal De Pediatria, 2023, 99, S37-S45.	0.9	4
86	Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host and Microbe, 2023, 31, 146-157.	5.1	57
87	Vaccine engineering & structural vaccinology. , 2022, , 55-86.		0
88	VDDB: A comprehensive resource and machine learning tool for antiviral drug discovery. , 2023, 2, .		0
89	Virus-like Magnetic Mesoporous Silica Particles as a Universal Vaccination Platform against Pathogenic Infections. ACS Nano, 2023, 17, 6899-6911.	7.3	5
90	Pandemic Preparedness and Response: Lessons From COVID-19. Journal of Infectious Diseases, 2023, 228, 422-425.	1.9	9
91	Progress in vaccine development for infectious diseasesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2023, 1524, 65-86.	1.8	3
92	Recent developments in antimicrobial surface coatings: Various deposition techniques with nanosized particles, their application and environmental concerns. Trends in Food Science and Technology, 2023, 135, 144-172.	7.8	8
93	Meeting Summary: Global Vaccine and Immunization Research Forum, 2021. Vaccine, 2023, 41, 1799-1807.	1.7	5
96	Factors Contributing to the Emergence of Viral Diseases. , 2023, , 3-69.		0
105	Bringing immunofocusing into focus. Npj Vaccines, 2024, 9, .	2.9	1

#	Article	IF	Citations